Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)

Phase: N/A Priority: Normal
NCT ID: NCT01257360 Org: User:
Start: 12/31/10 End: 07/31/16 Due: 07/31/17

Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01085058 Org: User:
Start: 05/31/03 End: 12/31/04 Due: 12/31/05

Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01388621 Org: User:
Start: 10/31/11 End: 07/31/15 Due: 07/31/16

Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02288741 Org: User:
Start: 08/31/01 End: 09/30/12 Due: 09/30/13

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT01423032 Org: User:
Start: 09/30/01 End: 05/31/09 Due: 05/31/10

Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01423695 Org: User:
Start: 02/28/01 End: 12/31/09 Due: 12/31/10

PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01374789 Org: User:
Start: 07/31/10 End: 03/31/12 Due: 03/31/13

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01088620 Org: User:
Start: 04/30/10 End: 01/31/14 Due: 01/31/15